Zealand Pharma

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

C ompany a nnouncement – No. 32 / 202 1

Zealand Pharma to participate in Jefferies Virtual Healthcare Conference

Zealand Pharma AS (ZEAL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zealand Pharma AS (ZEAL) Moves 8.3% Higher: Will This Strength Last?

Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q1 2021 Results - Earnings Call Transcript

C ompany  a nnouncement – No.  29 / 202 1

Zealand Pharma receives first FDA approval and prepares for launch of Zegalogue® (dasiglucagon) injection

Zealand Pharma launches long-term incentive program for Zealand's Executive Management and employees for 2021

C ompany a nnouncement – No. 27 / 202 1

Zealand Pharma Hosts Conference Call on May 12 at 4 pm CET (10 am ET) to Present First Quarter Results for 2021

C ompany a nnouncement – No. 25  / 202 1

Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes

Company announcement – No. 23  / 20 2 1

Zealand Pharma launches long-term incentive program for Zealand's Board of Directors and grants for 2021

Zealand Pharma's Annual General Meeting 2021

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

A new, easier-to-administer treatment for severe hypoglycemia has observers and investors wondering where its creators will go next.

With a New Diabetes Product Coming to Market, What Lies Ahead for Zealand Pharma Investors?

Total number of shares and voting rights in Zealand Pharma at March 31, 2021

Zealand Pharma to participate in upcoming investor conferences

Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes

Bristol-Myers

Pfizer

BioCryst Pharmaceuticals

Marker Therapeutics Inc

Pacira Pharmaceuticals

ProQR Therapeutics

Rubius Therapeutics Inc

Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest gainers of the week after the biopharma reported positive Phase 1/2 data for its RTX-240 in solid tumors.

FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings

Zealand Pharma convenes its Annual General Meeting 2021

Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q4 2020 Results - Earnings Call Transcript

Zealand Pharma: on Track for Potential First Product Launch and Establishing Commercial Operations in the United States

Total number of shares and voting rights in Zealand Pharma at February 28, 2021

Zealand Pharma Virtual R&D Day Materials Now Available with Live Q&A Session on March 5, 2021

Zealand Pharma Hosts Conference Call on March 11 at 4 pm CET (10am ET) to Present Full Year Results for 2020

Zealand Pharma to participate in SVB Leerink 9th Annual Global Healthcare Conference

Zealand Pharma's virtual Research & Development Day on March 5, 2021 will highlight progress across R&D pipeline and five-year strategy.

Zealand Pharma to Host R&D Day on March 5, 2021

Zealand Pharma announces completion of a directed issue and private placement of approx. 3.6 million new ordinary shares raising gross proceeds of approx.

Zealand Pharma announces directed issue and private placement corresponding to approx. 10% of existing share capital

News for Zealand Pharma Stock (ZEAL)